Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon, ladies and gentlemen, and welcome to Orion's earnings conference call and webcast for the financial period of January to March 2025. My name is Tuukka Hirvonen. I'm the head of IR here at Orion. In a few moments, as you know, we will start this event with CEO Lisa Graham's presentation, after which you will have the possibility to ask questions to her and also to our CFO, Mr. René Lindell. We will first be taking questions through the conference call lines, and then you also have the possibility to send in your questions through the webcast question form. We kindly ask you to present the company or organization you are representing before asking your question. And just before letting Lisa step in, just a reminder about the disclaimer regarding forward-looking statements. And with this, it's my pleasure to hand over to Lisa.
Thank you, Chuck, and good afternoon. On my behalf as well. And welcome to Orion Corporation 2025 webcast. I'll start with some highlights from our first quarter. I'm happy to tell you that all our four businesses have generated growth. And the fifth one, Fermion didn’t grow, but I will explain a bit about that later on. Also, our geographic expansion and R&D capabilities program is progressing, and we have opened an R&D site in Cambridge with the purpose of strengthening our pharmaceutical development for biologics. Also, there is a new key project in our clinical pipeline. This Phase III trial focuses on Levosimendan for pulmonary hypertension in a specific patient segment, and it is being conducted by Tenax Therapeutics, Inc. in the United States. On financials. The first quarter was excellent. Net sales grew 14.9% and our operating profit increased by 39.1%. And also, the operating profit margin improved from last year's first quarter. Cash flow decreased to some extent, mainly due to the timing of royalty payments and some milestone payments between quarters. Our net sales bridge looks a bit different than previously. If you remember earlier, we had net sales based on some of our biggest products, and now we have divided our net sales picture based on our divisions. Now, it's easier to follow up how each division is doing and which divisions are creating more or less growth. Since all three human divisions and Animal Health are creating growth. So, innovative medicines. Uh, €1,440.4 million in quarter one for branded products, €6.8 million, and generics, €1 million. Animal Health showed €3.3 million of growth. Fermion, as I already said, was not developing positively. But let's remember that this is only external sales. And then there are some internal transactions between Orion's other operations, which are very marginal here, amounting to 100 million. But all this ended up in €354.6 million of net sales in quarter one. Operating profit remained mostly consistent with previous figures. But we've made it a bit clearer with our texts. So, the first column here, €13.7 million, points to the change in volumes. So this shows the euros that the volume increase has generated, leading to significant growth. Then the second one includes the change that comes from changes in prices, costs, and product mix. So, a slight decrease there by 5.6 million. And then the third one is the effect of exchange rate changes on our gross margin from royalties. Clearly, the biggest contributor here is the fifth point, which is milestones compared to the last year's first quarter. A bit of a decrease there and then other operating income and expenses. And then at number seven here in column seven, you can see the fixed costs, which are mainly sales and marketing costs, in quarter one. And all this ended up close to 78 million in operating profit during the first quarter. Now I turn to Innovative Medicines, 70.4% growth here, which has almost created 100 million in sales in the first quarter. So we haven't yet exceeded the 100 million per quarter mark. And here on the right-hand side, you can see a clear phenomenon of a back-end loaded financial year in innovative medicines. You can see how the year ended in quarter 4 2024 with 152 million, actually. And now we started with 92 in the first quarter. And then, but you can clearly see that there is significant growth compared to the first quarter. So no worries if there is a change downwards from the last quarter of the previous year. We've explained earlier that the royalty rate increases significantly during the year as certain sales thresholds in euros are exceeded. Also, you can see here that the tablets that we deliver to Bayer reached an all-time high number. €38 million. Branded products. Almost 10% growth. And here you can also see a different type of split. Here we talk about CNS, not specific products. And we can see that the respiratory business is clearly the biggest one here. And the CNS business, back on a growth track, represents 30% of the branded products. And the entire Easyhaler portfolio grew by 8%. And the combination of budesonide-formoterol continued strong growth with almost 15%. And after a long time, Entacapone has reappeared on the top ten list. But CNS sales grew 5.7%, partly and mainly because of entacapone sales in Japan, but also because of some minor new products that are in that portfolio. Generics and consumer health. Almost 1% growth. A wonderful achievement in that portfolio. And here, the geographical split shows that Finland is the biggest single market for generics and consumer health. Scandinavia is the second biggest region, followed by Eastern Europe. And to reach this almost 1% growth. One of the main drivers was actually Scandinavia. This time, we were able to supply products that other companies were not able to supply in certain Scandinavian markets, which again shows and proves the excellent service level that we have in our generics business. Animal health showed a strong growth with a 10% increase. It was a bit lower in sales, although slower than last year, but still at a very good level in general in the animal health business. And then Fermion, as I already mentioned, declined. But let's remember this is only external sales, and a majority of the capacity is now bound to our internal own products. Top ten products. There are pluses and minuses. Plus 85% for Nubeqa; Easyhaler 8%. As I already said, Entacapone products showed a 6% increase. Japan is contributing to this growth as expected after the repatriation from Novartis. The minus on Dexdomitor and Domitor animal health sedatives is mainly due to the timing of shipments to our partners. So no, no worries there. There's been a lot of fluctuation between the quarters lately, and the Divina series, meaning mainly our estradiol gel product. 30% growth. I think that's after Nubeqa. That's actually our fastest growing product currently. Burana more or less at par with the previous year's first quarter. This is very normal. It's plus or minus 1 to 2% depending on the finish. Sales of Simdax and Dexdor portfolios are sliding down due to generic competition. Decision Trexan again, shipments from one quarter to another. And then a new entrant to this list is the Quetiapine products from our generic portfolio. It has climbed up to our top ten, mainly because Dexdor is going down, and I guess we'll see some of the biggest generics actually entering this list as generics. Dexdor and Simdax are sliding down, but we do sell Quetiapine in all the Nordic countries. And innovative medicines. Almost 30% of the revenues come from branded products, 22% from branded products, and 37% from generics. In the clinical pipeline, we have two Phase III projects ongoing with Nubeqa, which is very familiar to this audience. Aeronaut is already in the registration phase globally. The other step in phase three includes two projects ongoing with Open Orpha Omaha 1 and Omaha 2 for a different segment or phase of prostate cancer. And then one phase two study ongoing with Vessel Start, which is a continuation from the phase two study that we used to design the Phase III. The Phase III studies that we mentioned above include the Cupid's study and Odeum 212. And as I last time told, we are expanding that Phase I this year so that we have enough data to choose the right doses for the Phase II study. In the Tasipimidine study or program, we continue with phase two. This year we started with a very small phase 2A, and now we are expanding to the full-blown phase two. Then the new entrant, which we could call TNX 103 as Tenax calls it. This is an oral levosimendan. So the molecule is the same as in the Simdax product. But that's an IV product. This is an oral formulation, and it's used for treating pulmonary hypertension in patients with heart failure and an ejection fraction. Ejection rejection. Fraction of a certain magnitude, which in this case means a normal fraction. But these patients suffer from pulmonary hypertension. And this is quite a long story about why this appeared in our clinical pipeline. And maybe you do have questions regarding this, so I may shortly and briefly summarize the story. Already more than ten years ago, we made a deal with a company called Fixus, which at that time was an American company. They wanted to develop oral levosimendan for low cardiac output syndrome. Unfortunately, that study failed. We still continued a collaboration with the same people, now in the company called Tenax, and they managed and succeeded in getting finance for this program with levosimendan for this indication. And this came public in March this year. So this was the right time to bring it public here in our pipeline as this is our molecule and partner agreement. Like we have partner agreements with other companies such as Bayer, Merck, and also smaller companies. Then to a very different subject, sustainability and highlights from 2024. This was a huge job and I thank the team for this. I think all the companies have been working a lot to fulfill these European requirements. The pharmaceutical industry is all about patient safety and quality, and in 2024 we conducted 258 audits. Imagine that this means every week, there are approximately five audits. And if you count out, you know, Christmas and Easter and all the other holidays and bank holidays, it means that every week there are many groups of people from Orion visiting other companies, you know, checking how those factories are from the quality perspective. And I think this also tells a lot about our external suppliers, highlighting the number of suppliers we have. Then, of course, environment is another very important aspect. And here we've been able to reduce Scope 1 and Scope 2 emissions by 21% during 2024. And we have a very ambitious target, which is explained in our report, set to achieve by the year 2030. Safety of our colleagues is also very, very important both in our operations and in general for all of our colleagues, whether they are working in sales, R&D, or operations. To that purpose, we conduct safety discussions and safety sessions where we discuss topics in every other management meeting or team meeting. And you can see here that 72% of our line managers held this kind of safety session with their team every month. Of course, there might be teams that hold those more often, and maybe teams that hold them a bit less frequently. Our code of conduct was renewed last year, and here you can see that 94% of Orion's employees have had the code of conduct training last year. And of course, our target is 100%. And in most of the functions, it is 100%. But everybody understands that in a big organization, new people are constantly coming in and others are leaving. So, there are of course some limitations to reaching a full 100%. But that's definitely our aim because that's implemented in our onboarding process. Whenever anybody starts at Orion, they need to complete the code of conduct training from here on. Our outlook remains the same for this year as we've stated in February. So it's from €1,550 million to €1,650 million regarding net sales and €350 million to €450 million regarding operating profit. We will hold a Capital Markets Day in Helsinki on the 22nd of May. So I warmly welcome all of you to attend our Capital Markets Day, where we will share more light and wider and deeper information on each of our divisions, their product portfolios, current portfolios, their visions, and also current operations. And here you can see other upcoming events for the rest of this year: the half-year financial report in mid-July, and then, finally, October, the first nine months. At this point, I thank you for your attention, and I think it's time for questions. So I welcome our CFO, Rene Lindell, on stage to talk. I will join as well.
Thank you, Lisa, for the presentation. And as stated at the beginning of the event, we will first take questions through the conference call line. So at this point, I'd like to hand over to the operator, please.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Anssi Rousey from CIB. Please go ahead.
Yes. Thank you, and thank you for the presentation. I have a few questions, and I will go through them one by one. The first point concerns Nubeqa and its product sales, which were notably strong in Q1. So, have you had any discussions with Bayer, or do you have a view on this? If it was a bit of, you know, pre-buying to prepare for the possible tariffs or if it was just purely to meet strong underlying demand. Year-over-year growth was approximately 113% or something similar in product sales.
All right. It's a very good question in this current situation, whether this is related to tariffs; to my understanding, it is not related to tariffs but rather to the underlying demand from the markets and patients.
A very good question in this current situation that whether this is related to tariffs, to my understanding, this is not related to tariffs but really to underlying demand from the markets and patients. Thank you, Lisa, for the presentation. And the second one on your operational expenses, you mentioned in your report that these were lower than you anticipated. So which items are you referring to? And what explains the lower expenses? And also, do you expect that these, let's call them savings, will come back later this year? How do you see this?
Would you like to?
Yeah, I think overall our operating expenses grew year on year. If you compare to last year, and that is as planned. We've added more projects to our R&D early pipeline. We had the biologics there. So, of course, the costs have increased, particularly in sales and marketing. We have increased sales force to drive our business, especially in Europe. And of course, there's also inflation across the board otherwise. But I think what we refer to is it's a bit lower than we had anticipated overall; sometimes this is typical at the beginning of the year. Not everything starts as you have planned. And some of those costs are probably coming through during the year. So some catch-up is most likely to happen and is happening at the end of the year. But let's see, I mean, it's a typical start, I think, in Q1. But we expect some catch up on the expenses as well.
Thanks. Got it. And maybe finally on Levosimendan. So do you have any estimate when Tenax could complete its Phase III studies with the Levosimendan?
Uh, I think they have commented on this publicly.
And of course, there's also inflation across the board.
If you look at clinicaltrials.gov, the current level trial is expected to have a primary readout, uh, already in 26.
If you look at clinicaltrials.gov, the current trial is expected to have a primary readout already in 2026. However, uh, they need to have another Phase III trial, which is then the confirmatory trial, which can lead to product registration. And this is all based on their statements. And they are planning to start the other Phase III trial during this calendar year. So we will have to wait and see when they then expect that trial to read out.
But let's see, I mean, it's a typical start I think in Q1. And of course, there's also inflation across the board. And of course there's also inflation otherwise across the board. That was all from me.
The next question comes from Sammy Sarcomas from Danske Bank. Please go ahead.
Hi. I have three questions. We'll take this one by one. Uh, firstly, starting from, uh, U.S. import duties. Uh, can you comment if the discussed tariffs could have a material impact on Orion's Nubeqa franchise? And if you have means to mitigate the impacts through, for example, price increases or changes to your production setup.
Um, well, I think the situation in general with the import tariffs, whether it's pharmaceuticals or any other goods, is very unclear and it changes from day to day, so it's very difficult to make any conclusions at this time regarding our products. It's not yet known, regarding pharmaceuticals, at which level of the value chain those would be impacted. But of course, if such tariffs were to be set up, that would also have an impact on Orion's income. But it's still very early and too soon to say anything about it. Our biggest sales in the US, our biggest income in the US comes from Nubeqa. And I guess that was what you were referring to. And then we have nothing to do with the pricing of the product. And then that's really Bayer's question and should be discussed with Bayer. But any changes or tariffs that would impact that product would naturally also affect Orion to the certain magnitude that the agreements specify. So, we are not out of that scope by any means, but I think it's better to wait and see what will eventually happen with the tariffs.
Okay. Thank you. Moving on. I have two questions regarding the pipeline. Firstly, starting from the Tenax project. Uh, can you please discuss the market potential for the chosen indication? Um, what would roughly be your royalty rate? And how does the protection work as Simdax patents have already expired?
Well, let me start. And I'll let Tuukka continue with the market potential. I'm not sure what Tenax has really given out, but this one applies the same as with our projects. Licensed projects with Bayer and Merck. The best one to comment on this is really Tenax, but we can of course share that the agreement is such that the royalties are a really low two-digit number for us when the product hits the market. So I don't think there is any exact information. It's really something you can find in public sources. You know, this debate on what would be the market potential for this indication. Asian.
And if you have means to mitigate the impacts through, for example, price increases or changes to your production setup. Thank you. And then finally, you still haven't completed the phase one for ODM. Two. One. Two. Uh, are you still expecting to start phase two studies, uh, before the year-end, or is next year a more realistic time frame? Uh, if there is a delay into the next year, do you think this could have an impact on the R&D cost outlook for 2025?
Well, we communicated early this year in February that we will continue Phase I throughout 2025. So this is really the year when we complete the phase one study. There is new guidance by the FDA that requires collecting substantial data to define the right dosing for oncology drugs. So, based on that guidance, we will continue. And I think 2026 is a good estimation for the start of the Phase II. And yeah, you asked about the costs. The costs for the Phase I are included in our budget currently.
And then finally, uh, you still didn't complete, uh, the Phase I for ODM. And then finally, uh, you still didn't complete, uh, the Phase One for ODM. I don't have any further questions.
The next question comes from Sian Hamer from Jefferies. Please go ahead.
Hi there. Um, two questions from me. Um, so firstly, if you're allowed to disclose, is your price for Nubeqa with Bayer fixed in the contract, which would imply that Bayer would basically front all the impacts of potential tariffs. Um, and then secondly, is there any appetite within the company to divest any of the lower growth businesses, such as the generics or consumer health businesses? Thank you so much.
Oh, well, I'll start with Nubeqa. Uh, the price, of course, in the agreement between Bayer and Orion states the price at which we sell tablets to Bayer. And then again, as I think one of the previous persons asked, what would be the impact of tariffs to Orion? It really depends on which part of the value chain those tariffs would be hitting, you know, so whether it's really the price at which the tablet is transferred from Europe to us or whether it's the sales price in the US. So it's really difficult to say anything about it, but it is definitely sure that whatever spot or segment of the value chain it is, it will have an impact on Orion's royalty income as well. And the second question was.
Is there any appetite to divest other businesses like generics or Animal Health?
Thank you for reminding me. No, there is no appetite right now to divest any of our divisions.
Thank you.
The next question comes from Graham, from Parry. Please go ahead.
Hello? Graham, are you there?
Hi. Yeah. Sorry, it's Graham Parry from Bank of America. So, um, I just wanted to understand the follow-up on tariffs again. Um, in terms of the shipment of the product, is that actually shipped across the border in the US by Orion, or is it shipped across the border by Bayer? So who actually owns the product at the point of shipment? So, if we wanted to understand various scenarios on when there's a tariff announcement, how that exposure sits. So if it was, for example, Orion shipping it across the border, would you have a full exposure to the tariff or if it's Bayer, would Bayer have exposure to the tariff. But then, contractually, they could pass some of that down to you. Um, and secondly on tariffs, um, if Bayer were to raise the price in the US to pass on, uh, any impact of tariffs, presumably that would, um, also benefit your royalties. That's based on in-market sales in the US. Thanks.
Yeah. These are exactly very, very valid and good questions regarding the fact that we sell the tablets to Bayer. And that happens in Europe. So they ship it to us. Uh, and then of course, if there is some kind of a tariff on that one, they are responsible for it. But of course, there are many parts of the agreement that would partly affect us as well. You know, as I said, any tariff on any part of the value chain will also have an effect on us. Similarly, if they were to raise the price in the US, that would have an effect on our royalties as well. So that will continue.
So raising prices would have a mitigating impact. Exactly. If the tariffs are imposed, we would feel the impact proportionally. And if they can raise prices, then we also benefit from that. Exactly.
So it goes both ways.
Yeah, that's super clear. So you effectively share the tariff regardless of where it is. And you benefit from any price increase in royalties, so that you're effectively sharing it contractually. Um, and then the second question for me is just when should we expect the cost of the Cambridge R&D facility to start to appear in your R&D costs? Thanks.
Those costs are already included in the amount that we anticipate will occur in this year's R&D budget.
So just to be clear, so I understand that's in your guidance, but have they started to be incurred in Q1 or is this something which is going to be more back-end loaded into the cost for the year?
Yeah, it will be more back-ended clearly. Yes.
And if they can raise prices, then we also benefit from that.
The next question comes from Ansi Rousey from Seb. Please go ahead.
Yes, I have one question left actually, and it's on Divina. So really strong growth in Q1. But was there something extraordinary, or is it just picking up in the pace of growth?
It is picking up. It's been picking up actually for a few years now. If you look at the numbers, I think it started to pick up right after Covid over the last few years. First with the 10% growth, then 5% growth, followed by 10% growth, and finally 15-20%. And it's actually accelerating all the time. So now it was 30%. And that's really a market demand for this type of treatment. This is estradiol. So. So it's really the market demand for this type of product.
And if they can raise prices, then we also benefit from that. And if they can raise prices, then we also benefit from that.
There are no more questions at this time. So, I hand the conference back to the speakers.
Thank you. We have a few questions coming online, but before going there, we actually forgot to answer one of Sammy's questions regarding the Levosimendan protection.
Yes. Well, again, Tenax would be the right party to ask about the protection. And you are correct. The molecule levosimendan is not protected anymore. In the US, you can get data protection based on the data you produce in your clinical studies for specific indications. So I would assume that the market protection would cover that. That's actually called data protection or market protection. So the business case is based on that data protection.
Thank you, Lisa. Then we can turn to the webcast questions we have. First, a couple of questions from online from Hautala at Nordea. So does Orion have other clinical trials being developed by partners that could enter Orion's pipeline in the future, and if so, can you mention what is in Phase II in such cases? I guess I am only referring to the Levosimendan case here.
I fully understand this game. It might seem that it came out of nowhere, but that's not really the case. We report key clinical projects, which for us means Phase III projects. So clearly we are not reporting phase two, except the Stupidus, which is still ongoing. There might be Phase IIs if we really think that they are key ones. And I'm really trying to think about our partners, if there is something going on that would result in a similar type of race to our clinical pipeline, but nothing comes to my mind currently.
Of course, regarding all the trials that we have stated, we will include Phase III, but if you take a deeper look at MSD or Merck. They have some phase twos ongoing, for instance, with combinations targeting prostate cancer.
That's very, very true. And I guess they've shared some information on those. And I hope actually that we could discuss more of those in our capital market day.
Absolutely. All right then moving on. Another question from online and still regarding the Tenax Levosimendan case. Can you further explain Orion's role here? What part of the intellectual rights are owned by Orion, and what will be Orion's role in the future?
Our role is really such that we've licensed the rights to develop oral levosimendan for this indication to Tenax Therapeutics, Inc. We also develop the pharmaceutical products themselves since we know Levosimendan very well. It's quite natural that we are responsible for the product development here. And of course, it remains to be seen whether we manufacture the product or not in the future. Otherwise, I think that's, in all its simplicity, our role in this agreement.
Great. Thanks, Lisa. Then moving on. Another question regarding, uh, the R&D pipeline coming from Mr. Alap Das. And this is actually referring to Orion 111. Can we expect the preclinical data on Odeon 111 at any conference? Do we have any plans to publish the preclinical data? I'm sure that the clinical data will probably be published at some point, I'm sure.
But this is something that you will also hear more about at our Capital Markets Day. So welcome to listen to our Head of R&D. Uh, since I can't say whether we are going to publish that or not, or when we are going to publish that.
Thanks, Lisa. Then moving on. We have one question regarding branded products and entacapone. So this comes from Alexander Huitfeldt from Shinko. Beyond Entacapone sales in Japan, are there any other key initiatives or growth drivers within your CNS portfolio that you are currently developing or prioritizing? Are there any products or indications you're especially focused on going forward?
Hmm. Excellent questions. Yes, we are focusing on CNS, specifically on Parkinson's disease. Orion is still very well known in that sphere, and we've been approached by many companies that have this type of value-added products, which are maybe combinations of older molecules or new formulations of older molecules for Parkinson's disease or other neurodegenerative diseases. So we are building a portfolio around Stalevo, Comtan, and Comtess currently. And there. I think the first launch would be this year in Finland for this type of a very microscopic or small, um. It's a kind of powder product of entacapone combined with some other drugs that would allow patients to titrate their dose in a better way than with entacapone alone. So it would be a segment for a rather late stage of the disease before much more intensive treatments like Intestinal dopamine or other types of treatment. So, so there will be new products. And again, I repeat myself, I'm sure Haupun, who leads the Branded Products division, will share more light on this portfolio at the Capital Markets Day.
Thanks, Lisa. Then we can continue on Capital Markets Day. There's a question from Christopher and Mark from Alan's Bank asking if you will provide additional information regarding the capital allocation strategy during the CMD? The balance sheet is solid at this point. It seems there are a number of M&A possibilities out there. Or is it still dividend-focused?
Yeah, I'm sure we'll also discuss the capital allocation at that point.
But maybe it's good to remind that we haven't changed our financial objectives as they are today. Then moving on. We have one question from Marty from OP regarding potential tariffs, could you please remind us of the key advantages that Nubeqa has versus competitors, and why US doctors would prefer Nubeqa over other products despite the potential tariffs?
Well, we have discussed the benefits of Nubeqa earlier. It's very much about the side effect profile. It's as you would say, it's a very kind drug. You know, typically cancer drugs have this and that, you know, as side effects. But we do know from experience and from what doctors are telling us that the side effect profile is very favorable, and both they and the patients appreciate that type of product. Whether this plays a role when you talk about tariffs, I don't really know. It's very difficult to define any such criteria for any drug or any group of drugs that would make them more preferable than others. If tariffs are set, of course, I exclude pricing from this. Pricing would definitely play a role there. But otherwise, I think it's really the known effects of Nubeqa, both regarding the side effects and the efficacy of the drug.
Thank you, Lisa. Now it seems that we have exhausted the questions from online. Thank you. At this point, we welcome lively discussions and questions. So at this stage, it's time to conclude the event. Lisa, any final words?
Well, I thank you for your attention and, of course, all your colleagues for a successful first quarter. And we continue the year as we have promised within our outlook. At this point, thank you for the lively discussions and questions. Thank you.



















